

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
23 January 2003 (23.01.2003)

PCT

(10) International Publication Number  
**WO 03/006458 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 401/12**,  
A61K 31/505, A61P 27/02

CH-4148 Pfeffingen (CH). **POMBO VILLAR, Esteban**  
[CO/CH]; St. Johannis-Parkweg 5, CH-4056 Basel (CH).

(21) International Application Number: PCT/EP02/07594

(74) Agent: **GROS, Florent**; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).

(22) International Filing Date: 8 July 2002 (08.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
01116553.7 9 July 2001 (09.07.2001) EP

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except AT, US*): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR).

(71) Applicant (*for AT only*): **NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

**Published:**  
— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MARKSTEIN, Rudolf** [DE/DE]; Ernst-Reuter-Strasse 2, 79618 Rheinfelden (DE). **GULL, Peter** [CH/CH]; Moosackerweg 3,

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **BENZO [G] QUINOLINE DERIVATIVES FOR TREATING GLAUCOMA AND MYOPIA**

(57) Abstract: The invention provides a compound of formula I wherein A, B, X, Y and R<sub>1</sub> are as defined in the description, and a process for preparing them. The compounds of formula I are useful as pharmaceutical agents for the treatment of glaucoma and myopia.




**WO 03/006458 A1**

- 1 -

## BENZO[G]QUINOLINE DERIVATIVES FOR TREATING GLAUCOMA AND MYOPIA

The present invention relates to novel benzo[g]quinoline derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.

More particularly the present invention provides a compound of formula I



wherein

A and B are each H or form together an additional bond,

X is CH<sub>2</sub> or CO,

Y is O, S, NR<sub>2</sub> [R<sub>2</sub> being H or (C<sub>1-4</sub>)alkyl], CH<sub>2</sub> or O-CH<sub>2</sub>, and

R<sub>1</sub> is H or (C<sub>1-4</sub>)alkyl

in free base or acid addition salt form.

The above-defined alkyl groups preferably represent methyl.

When A and B are each H, the X-Y-pyrimidine substituent preferably presents the configuration 3R.

X is preferably CH<sub>2</sub>.


Y is preferably O or S, even more preferably S.

- 2 -

$R_1$  is preferably methyl, more preferably methyl in position 4 of the addressed pyrimidine.

In a preferred embodiment A and B each represents H, X is  $\text{CH}_2$ , Y represents S and  $R_1$  is methyl.

In a further aspect the invention provides a process for the production of the compounds of formula I and their acid addition salts, whereby in a compound of formula II



wherein A, B, X, Y and  $R_1$  are as defined above and  $R_3$  is  $(\text{C}_{1-4})$ alkyl, the alkoxy group is converted into a hydroxy group, and the compounds of formula I thus obtained are recovered in free base or acid addition salt form.


The reaction can be effected according to known methods, e.g. using hydrobromide acid or boron tribromide. In formula II,  $R_3$  is preferably methyl.

Working up the reaction mixtures obtained according to the above process and purification of the compounds thus obtained may be carried out in accordance to known procedures.

Acid addition salts may be produced from the free bases in known manner, and vice versa. Suitable acid addition salts for use in accordance with the present invention include for example the hydrochloride.

The starting compounds of formula II wherein A and B are each H may be produced from the corresponding compounds of formula III<sub>a</sub>


- 3 -



wherein R<sub>3</sub> is as defined above, for example as described in Example 1.

The compounds of formula III<sub>a</sub> are known or may be produced in analogous manner to known procedures.

The starting compounds of formula II wherein A and B together form an additional bond may be produced from the corresponding compounds of formula III<sub>b</sub>



wherein R<sub>3</sub> is as defined above.

The compounds of formula III<sub>b</sub> are known or may be produced in analogous manner to known procedures.

The compounds of formula I and their physiologically acceptable acid addition salts, referred to hereinafter as agents of the invention, exhibit valuable pharmacological properties in animal tests and are therefore useful as pharmaceuticals.

In particular, the agents according to the invention effect a decrease on the intraocular pressure in rabbits, at concentrations of e.g. 10 to 100  $\mu$ M. Male rabbits of ca. 2.5 kg are fixed in cages leaving their heads free. The solutions with the compound to be tested are

- 4 -

applied to the right eye and the placebo solutions to the left eye (2 drops each, i.e. ca. 40µl). The eyes are firstly anaesthetized with a solution containing Novesine (0.4 %) and Fluorescein (0.05 %) and the ocular pressure is determined at various intervals after administration (10, 20, 30, 60, 90, 120, 180 and 240 minutes), whereby an applanation tonometer according to Goldberg is used.

The agents of the present invention, in particular the preferred agents, exhibit a surprising strong efficacy in lowering the intraocular pressure (IOP) and an excellent duration of action. Moreover, they exhibit an excellent tolerability.

The agents according to the invention are therefore in particular useful in the treatment of glaucoma and myopia. A more preferred use is glaucoma treatment, lowering of IOP.

For the above mentioned indication, the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.1 to about 10 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 5 to about 200 mg, preferably about 10 to about 100 mg of the compound conveniently administered in divided doses up to 4 times a day or in sustained release form.

The agents of the invention may be administered in free form or in pharmaceutically acceptable salt form. Such salts may be prepared in conventional manner and exhibit the same order of activity as the free compounds.

Accordingly the present invention provides an agent of the invention for use as a pharmaceutical, e.g. in the treatment of glaucoma and myopia.

The present invention furthermore provides a pharmaceutical composition comprising an agent of the invention in association with at least one pharmaceutically acceptable diluent or carrier. Such compositions may be formulated in conventional manner. Unit dosage forms contain, for example, from about 0.25 to about 50 mg of an agent according to the invention.

- 5 -

Agents according to the invention may be administered by any conventional route, for example parenterally e.g. in form of injectable solutions or suspensions, or enterally, preferably orally, e.g. in the form of tablets or capsules.

More preferably, they are applied topically to the eye in about 0.0001 to 2 %, preferably in about 0.001 to 0.5 %, and more preferably in about 0.01 to 0.1 % ophthalmological solutions.

The ophthalmic vehicle is such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye.

The pharmaceutically acceptable ophthalmic vehicle may be e.g. an ointment, vegetable oil, or an encapsulating material.

In accordance with the foregoing, the present invention also provides an agent of the invention for use as a pharmaceutical in the treatment of glaucoma and myopia.

Moreover the present invention provides the use of an agent of the invention, for the manufacture of a medicament for the treatment of glaucoma and myopia.

In still a further aspect the present invention provides a method for the treatment of glaucoma and myopia in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of an agent of the invention.

The present invention relates also to any compound disclosed in the working examples. It further relates to any independent and/or dependant claims disclosed infra.

The following examples illustrate the invention. The temperatures are given in degrees Celsius and are uncorrected.

**Example 1****[3R,4aR,10aR]-1-methyl-3 $\beta$ -{4-methyl-1,3-pyrimidin-2yl}thiomethyl-6-hydroxy-1,2,3,4,4a $\alpha$ ,5,10,10a $\beta$ -octahydrobenzo[g]quinoline****a) [3R,4aR,10aR]-1-methyl-3 $\beta$ -hydroxymethyl-6-methoxy-1,2,3,4, 4a $\alpha$ ,5,10, 10a $\beta$ -octahydrobenzo[g]quinoline**

To a solution of 5.78g (20 mM) [3R,4aR,10aR]-1-methyl-3 $\beta$ -methoxycarbonyl-6-methoxy-1,2,3,4,4a $\alpha$ ,5,10,10a $\beta$ -octahydrobenzo[g]quinoline in 100 ml toluene, a solution of 12 ml SDBA (70 % in toluene, 42 mM) is added in drops under argon at room temperature within one hour. Then 10 ml NaOH (30 %) are added in drops to the ice cooled reaction mixture. The precipitated crystals are filtered off, washed with water and toluene and dried. The resulting title compound has a m.p. of 148°;  $[\alpha]_D^{20} = -120^\circ$  (c = 0.425 in ethanol).

**b) [3R,4aR,10aR]-1-methyl-3 $\beta$ -mesyloxymethyl-6-methoxy-1,2,3,4,4a $\alpha$ ,5,10, 10a $\beta$ -octahydrobenzo[g]quinoline**

12 ml (153 mM) methanesulfochloride are added in drops to a solution of 20 g (76.5 mM) of the compound obtained under a) in 150 ml pyridine at room temperature. The temperature is kept below 45° by ice cooling. After stirring for 2 hours at room temperature, the solution is adjusted to pH 7-8 with saturated KHCO<sub>3</sub> solution at 0° and extracted with ethylacetate. After drying over Na<sub>2</sub>SO<sub>4</sub>, filtering and concentrating by evaporation, the title compound is obtained as beige crystals and directly used for the next step.

**c) [3R,4aR,10aR]-1-methyl-3 $\beta$ -{4-methyl-1,3-pyrimidin-2yl}thiomethyl-6-methoxy-1,2,3,4,4a $\alpha$ ,5,10,10a $\beta$ -octahydrobenzo[g]quinoline**

A solution of 6 g (17.7 mM) of the compound obtained under b) and 3.4 g (27 mM) 2-mercapto-4-methyl-1,3-pyrimidin in 60 ml dimethylformamide is mixed with 6 ml 2N NaOH and stirred at 65° for 18 hours. The so obtained suspension is concentrated by evaporation. The crude product crystallises. The suspension is cooled to 5-10°, washed with ethylacetate and dried. Chromatography on silicagel with ethylacetate containing 10 % ethanol and 0.01 % NH<sub>3</sub> yields the title compound as beige crystals.

- 7 -


- d) [3R,4aR,10aR]-1-methyl-3β-{ 4-methyl-1,3-pyrimidin-2yl }thiomethyl-6-hydroxy-1,2,3,4,4aα,5,10,10aβ-octahydrobenzo[g]quinoline

To a solution of 4.06 g (11 mM) of the product obtained under c) in 250 ml methylenechloride, 40 ml of boron tribromide (1 M in methylenechloride) are slowly added in drops at a temperature of -40°. The suspension is stirred for 2 hours at room temperature, neutralized with NH<sub>3</sub> and extracted with a mixture of 150 ml methylenechloride and 100 ml isopropanol. After drying over Na<sub>2</sub>SO<sub>4</sub>, filtering and concentration by evaporation, the title compound crystallises. The corresponding hydrochloride crystallises from methanol/ethanol 1:1 during evaporation. M.p. 254°;  $[\alpha]_D^{20} = -90^\circ$  (c = 0.540 in ethanol/water 1:1). C<sub>20</sub>H<sub>25</sub>N<sub>3</sub>OS (HCl), MW=391.97.



**CLAIMS:**

1. A compound of formula I



wherein

A and B are each H or form together an additional bond,


X is CH<sub>2</sub> or CO,

Y is O, S, NR<sub>2</sub> [R<sub>2</sub> being H or (C<sub>1-4</sub>)alkyl], CH<sub>2</sub> or O-CH<sub>2</sub>, and

R<sub>1</sub> is H or (C<sub>1-4</sub>)alkyl

in free base or acid addition salt form.

2. A process for the preparation of a compound of formula I as defined in claim 1, or a salt thereof, which includes the step of converting, in a compound of formula II



wherein A, B, X, Y and R<sub>1</sub> are as defined in claim 1 and R<sub>3</sub> is (C<sub>1-4</sub>)alkyl, the alkoxy group into a hydroxy group and recovering the thus obtained compound of formula I in free base or acid addition salt form.

3. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.
4. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment of glaucoma and myopia.
5. A pharmaceutical composition comprising a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.
6. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the treatment of glaucoma and myopia.
7. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of glaucoma and myopia.
8. A method for the treatment of glaucoma and myopia in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form.

## INTERNATIONAL SEARCH REPORT

Int. Application No.  
PCT/EP 02/07594

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/12 A61K31/505 A61P27/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 01444 A (NOVARTIS A.-G., SWITZ.; GULL, PETER; MARKSTEIN, RUDOLF; SEILER, MAX PET) 15 January 1998 (1998-01-15) the whole document	1-7
Y	EP 0 659 430 A (SANDOZ LTD., SWITZ.; SANDOZ-PATENT-G.M.B.H.; SANDOZ ERFINDUNGEN VERWALT) 28 June 1995 (1995-06-28) the whole document	1-7
Y	EP 0 512 952 A (SANDOZ-PATENT-G.M.B.H., GERMANY) 11 November 1992 (1992-11-11) the whole document	1-7
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## ° Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

16 October 2002

Date of mailing of the international search report

28/10/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Schuemacher, A

## INTERNATIONAL SEARCH REPORT

Int      nal Application No

PCT/EP 02/07594

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 03054 A (SANDOZ LTD., SWITZ.; SANDOZ-PATENT-GMBH; SANDOZ-ERFINDUNGEN VERWALTUNGS) 30 January 1997 (1997-01-30) table p.10, Ex.7 -----	1

# INTERNATIONAL SEARCH REPORT

ational application No.  
PCT/EP 02/07594

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claim 8 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

In International Application No

PCT/JP 02/07594

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9801444	A	15-01-1998	AT 211470 T	15-01-2002
			AU 719119 B2	04-05-2000
			AU 3542297 A	02-02-1998
			BR 9710218 A	10-08-1999
			CA 2257646 A1	15-01-1998
			CZ 9900027 A3	17-03-1999
			DE 69709869 D1	28-02-2002
			DE 69709869 T2	14-08-2002
			DK 912553 T3	22-04-2002
			WO 9801444 A1	15-01-1998
			EP 0912553 A1	06-05-1999
			ES 2170402 T3	01-08-2002
			JP 2000514075 T	24-10-2000
			NO 990035 A	05-01-1999
			NZ 333311 A	23-06-2000
			PL 330723 A1	24-05-1999
			PT 912553 T	28-06-2002
			SI 912553 T1	30-06-2002
			SK 399 A3	11-06-1999
			TR 9900016 T2	21-04-1999
			TW 378209 B	01-01-2000
			US 6057334 A	02-05-2000
			ZA 9706072 A	08-01-1999
EP 0659430	A	28-06-1995	AU 689510 B2	02-04-1998
			AU 8152294 A	29-06-1995
			CA 2138421 A1	22-06-1995
			CN 1109332 A	04-10-1995
			CZ 9403240 A3	13-09-1995
			EP 0659430 A1	28-06-1995
			HU 71497 A2	28-11-1995
			JP 7215872 A	15-08-1995
			NO 944906 A	22-06-1995
			PL 306367 A1	26-06-1995
			SK 155994 A3	11-07-1995
			ZA 9410210 A	21-06-1996
EP 0512952	A	11-11-1992	DE 4114325 A1	05-11-1992
			AU 656768 B2	16-02-1995
			AU 1529192 A	05-11-1992
			CA 2067648 A1	03-11-1992
			CS 9201311 A3	18-11-1992
			EP 0512952 A1	11-11-1992
			FI 921957 A	03-11-1992
			HU 61011 A2	30-11-1992
			IE 921374 A1	04-11-1992
			JP 5170762 A	09-07-1993
			MX 9202024 A1	01-11-1992
			NO 921723 A	03-11-1992
			NZ 242562 A	26-08-1994
			RO 109333 B1	30-01-1995
			US 5262422 A	16-11-1993
			ZA 9203187 A	01-11-1993
WO 9703054	A	30-01-1997	AT 201199 T	15-06-2001
			AU 703325 B2	25-03-1999
			AU 6612096 A	10-02-1997
			BR 9609326 A	25-05-1999

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/EP 02/07594

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9703054 A		CA 2224436 A1	30-01-1997
		CN 1193964 A	23-09-1998
		CZ 9800016 A3	15-04-1998
		DE 69612852 D1	21-06-2001
		DE 69612852 T2	04-10-2001
		DK 839136 T3	06-08-2001
		WO 9703054 A1	30-01-1997
		EP 0839136 A1	06-05-1998
		ES 2158327 T3	01-09-2001
		HU 9802937 A2	28-10-1999
		IL 122854 A	06-12-2000
		JP 11509197 T	17-08-1999
		NO 980043 A	05-01-1998
		NZ 313606 A	29-07-1999
		PL 324106 A1	11-05-1998
		PT 839136 T	28-09-2001
		RU 2158738 C2	10-11-2000
		SI 839136 T1	31-10-2001
		SK 1798 A3	03-06-1998
		TR 9800011 T1	21-04-1998
		US 5885988 A	23-03-1999